Oncodesign SERVICES is an innovation-based solutions and expertise provider in Drug Discovery in Oncology, Immuno-oncology, Infectious Diseases (Covid-19) and Inflammatory Diseases. Benefiting from multi-disciplinary teams and seasoned management with long-standing experience in pharmaceutical industry and innovative services, DRIVE-SM (Small Molecule) is an integrated drug discovery engine configured to discover, generate and accelerate the entry of new chemical entities into the clinic. DRIVE-SM (Small Molecule) from Hit Finding to IND filing encloses multiple innnovative hit-finding/screening capabilities, medicinal chemistry, computational chemistry, in vitro biology, ADME / DMPK, in vivo pharmacology, pharmaco-imaging/theranostic and safety assessment all applied in one-stop shop to drug discovery programs in oncology, immuno-oncology auto-immune/ inflammatory diseases.
Wednesday, 18th November, 2020
10:00am GMT (UTC+0)
hosted by Lilly Xu, Ph.D. Senior Vice President, DMPK & Exploratory Toxicology Dept, ChemPartner